to anticancer therapy. Nevertheless, advanced age alone should not be the only criteria to preclude effective treatment that could improve quality of life or lead to a survival benefit in older patients. 6 , 7 Surgery, radiation therapy (RT
Search Results
Noam VanderWalde, Reshma Jagsi, Efrat Dotan, Joel Baumgartner, Ilene S. Browner, Peggy Burhenn, Harvey Jay Cohen, Barish H. Edil, Beatrice Edwards, Martine Extermann, Apar Kishor P. Ganti, Cary Gross, Joleen Hubbard, Nancy L. Keating, Beatriz Korc-Grodzicki, June M. McKoy, Bruno C. Medeiros, Ewa Mrozek, Tracey O'Connor, Hope S. Rugo, Randall W. Rupper, Dale Shepard, Rebecca A. Silliman, Derek L. Stirewalt, William P. Tew, Louise C. Walter, Tanya Wildes, Mary Anne Bergman, Hema Sundar, and Arti Hurria
Ania Syrowatka, James A. Hanley, Daniala L. Weir, William G. Dixon, Ari N. Meguerditchian, and Robyn Tamblyn
vary based on the period of cancer care, specifically during hospital-based treatment (ie, treatments received within a hospital on either an inpatient or outpatient basis, specifically breast cancer surgery, chemotherapy, and/or radiation) and
Urshila Durani, Dennis Asante, Thorvardur Halfdanarson, Herbert C. Heien, Lindsey Sangaralingham, Carrie A. Thompson, Prema Peethambaram, Fernando J. Quevedo, and Ronald S. Go
staging period was defined as 60 days before to 60 days after surgery. The surveillance period was from 60 days after surgery until death or last follow-up. “High use” in the surveillance cohort was defined as >2 CT, PET, or PET/CT scans in 1 year, based
Vlad Sandulache, Anita Sabichi, George Chen, and Scott Charnitsky
generate baseline data (2000–2010) for: (1) time to treatment (surgery, 24 days; radiation, 48 days) and (2) treatment package time <100 days compliance (68%). We developed a tool available to providers and clinic staff to prospectively track patients from
Margaret von Mehren, R. Lor Randall, Robert S. Benjamin, Sarah Boles, Marilyn M. Bui, Ernest U. Conrad III, Kristen N. Ganjoo, Suzanne George, Ricardo J. Gonzalez, Martin J. Heslin, John M. Kane III, Henry Koon, Joel Mayerson, Martin McCarter, Sean V. McGarry, Christian Meyer, Richard J. O'Donnell, Alberto S. Pappo, I. Benjamin Paz, Ivy A. Petersen, John D. Pfeifer, Richard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, William D. Tap, Jeffrey D. Wayne, Mary Anne Bergman, and Jillian Scavone
, positive family history for desmoid tumors, abdominal surgery, and the APC mutation site were identified as significant risk factors for the development of desmoid tumors. 25 The median age at diagnosis was 31 years, with most desmoid tumors arising in
Emily Chan, Paul E. Wise, and A. Bapsi Chakravarthy
performed to rule out synchronous primaries in the colon or rectum. If obstruction precludes this at initial evaluation, it should be performed before definitive surgery to determine the type of surgery required. If full endoscopic evaluation is not
Clayton A. Smith and Lisa A. Kachnic
, historical rates of local failure following surgery alone using older techniques were ≥25%. 2 The development of total mesorectal excision (TME) with sharp dissection of mesorectal contents further reduced the rates of local recurrence to as low as 8%. 3
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2021
Featured Updates to the NCCN Guidelines
Susan M. Swetter, John A. Thompson, Mark R. Albertini, Christopher A. Barker, Joel Baumgartner, Genevieve Boland, Bartosz Chmielowski, Dominick DiMaio, Alison Durham, Ryan C. Fields, Martin D. Fleming, Anjela Galan, Brian Gastman, Kenneth Grossmann, Samantha Guild, Ashley Holder, Douglas Johnson, Richard W. Joseph, Giorgos Karakousis, Kari Kendra, Julie R. Lange, Ryan Lanning, Kim Margolin, Anthony J. Olszanski, Patrick A. Ott, Merrick I. Ross, April K. Salama, Rohit Sharma, Joseph Skitzki, Jeffrey Sosman, Evan Wuthrick, Nicole R. McMillian, and Anita M. Engh
constrained sites (eg, face, palms, soles), in addition to the presence of atypical/actinic melanocytic hyperplasia in the LM subtype (high-CSD melanoma) which often confounds histologic assessment of margin status. 88 , 105 – 117 For this reason, surgery
Fikri İçli, Hakan Akbulut, Shouki Bazarbashi, Mehmet Ayhan Kuzu, Mohandas K. Mallath, Kakil Ibrahim Rasul, Scott Strong, Aamir Ali Syed, Faruk Zorlu, and Paul F. Engstrom
in accordance with the NCCN Guidelines, except those related to questions number 1 and 10. According to the results, 69% did not perform routine chest CT before surgery for all patients with colon cancer. With regard to first-line chemotherapy for
William C. Huang and Bernard H. Bochner
Herr H . Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma . J Clin Oncol 1999 ; 17 : 2546 – 2552 . 50
